Results 61 to 70 of about 9,828 (193)
Multitarget Drug Design for Cardiovascular Disease: Bridging Chemistry and Medicine
Many pathophysiological pathways associated with cardiovascular diseases involve multiple drug targets. This article reviews recent advances in the development of pharmacological compounds capable of simultaneously modulating multiple mechanisms. Multitarget drugs offer a promising therapeutic approach for complex cardiovascular disorders, including ...
Gyuzel Y. Mitronova +3 more
wiley +1 more source
BackgroundThere is no consensus on the most effective and best tolerated first‐line antiarrhythmic treatment for fetal tachyarrhythmia. The purpose of this systematic review and meta‐analysis was to compare the efficacy, safety, and fetal–maternal ...
Tarek Alsaied +7 more
doaj +1 more source
This retrospective single‐center cohort study assessed safety and outcomes related to the practice of holding AVNBA prior to elective DCCV. Procedural‐level analyses comparing AVNBA holding 24 h prior to cardioversion showed that holding AVNBAs prior to elective DCCV was not associated with meaningful differences in short‐term arrhythmic safety ...
Zach Caverley +2 more
wiley +1 more source
AGE-DEPENDENCE OF FLECAINIDE PHARMACOKINETICS
Aim: The aim of the study was to evaluate the relationship between age and the pharmacokinetics of flecainide. Methods: Fifteen patients with frequent premature ventricular contractions and with normal renal function were selected and divided into two ...
SPEDICATO L +6 more
core
Altered flecainide disposition in healthy volunteers taking quinine.
The pharmacokinetics of flecainide and its two sequential metabolites, both free and conjugated, its pharmacodynamics, and the influence of simultaneously administered quinine, have been studied in 10 healthy subjects.
Reymond-Michel, G. +5 more
core +1 more source
Flecainide is an antiarrhythmic agent that has been reported to have numerous cardiotoxic effects, including the development of arrhythmias and the reduction of left ventricular ejection fraction (LVEF).
Morris, Desiree +4 more
core +1 more source
Thoracoscopic Gemini S box ablation with confirmed entry and exit block achieved sinus rhythm in 87.0% of 23 patients at 1 year, all off Class I/III antiarrhythmic drugs. The box remained isolated at two of three reinterventions, with recurrence outside it involving the superior vena cava in all three.
Michal Gruszczynski +5 more
wiley +1 more source
Flecainide is class Ic antiarrhythmic drug with a narrow therapeutic range. Adverse drug reactions during flecainide therapy are predominately cardiac in nature. Severe neurological adverse drug reactions have rarely been described.
Joseph Blunck +2 more
core +1 more source
Flecainide use in arrhythmic patients who have structural heart disease
Background: Current guidelines recommend the use of only on a limited basis in patients with normal or minimal structural heart disease. The CAST study, the only randomized controlled trials, showed increased mortality from long-term flecainide use in ...
Naruepat Sangpornsuk +5 more
doaj +1 more source
Background: Flecainide, a class Ic antiarrhythmic agent, has long been contraindicated in structural heart disease (SHD) due to findings of the Cardiac Arrhythmia Suppression Trial (CAST).
Dimitrios Tsiachris +10 more
doaj +1 more source

